Trubion Announces Presentation of Positive TRU-016 Data at ASCO
June 02 2008 - 5:00PM
PR Newswire (US)
TRU-016 Produces Significant Anti-Tumor Activity and Long-Term
Tumor Regression in Pre-Clinical Studies SEATTLE, June 2
/PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc.
(NASDAQ:TRBN) today announced presentation of positive pre-clinical
data showing that Trubion's TRU-016 has potent anti-tumor activity
and induces significant long-term tumor eradication in a human
tumor xenograft model in which rituximab failed to induce durable
responses. TRU-016 is Trubion's proprietary CD37-targeted therapy
in development for B-cell malignancies such as chronic lymphocytic
leukemia (CLL) and non-Hodgkin's lymphoma (NHL). ASCO Abstract 3074
TRU-016, a small modular immunopharmaceutical (SMIPTM) candidate,
targets the CD37 antigen on human B cells. Data from both in vivo
and in vitro studies presented at the American Society of Clinical
Oncology (ASCO) 2008 Annual Meeting showed TRU-016 has potent
anti-tumor activity and induces significant long-term tumor
eradication in a human tumor xenograft model in which rituximab
failed to induce durable responses. Moreover, TRU-016 treatment
produced anti-tumor activity that resulted in increased survival
and a significant delay in tumor growth in NHL xenografts. These
data were presented during a poster session at the ASCO Annual
Meeting on June 1, 2008, from 2-4 p.m. CDT. The poster is available
on the investor section of Trubion's Web site:
http://investors.trubion.com/events.cfm. "Data from this study,
combined with data from previous studies, reinforce our belief that
TRU-016's novel mechanism of action may provide patients with a
potent new therapeutic option for the treatment of B-cell
malignancies," said Peter Thompson, M.D., FACP, president, chief
executive officer and chairman of Trubion. "TRU-016 represents a
first-in-class product opportunity with an exciting, differentiated
pre-clinical profile. The demonstrated ability of TRU-016 to kill
tumor cells through powerful apoptotic signaling as well as potent
ADCC-mediated activity, combined with its synergy with
chemotherapies and anti-CD20 therapies, adds to our confidence that
this drug, either alone or in combination with other effective
therapies, may offer meaningful benefits to patients with these
diseases. We look forward to the results of our ongoing Phase 1/2
clinical trial currently evaluating TRU-016 in CLL patients." About
Trubion Trubion is a biopharmaceutical company that is creating a
pipeline of novel protein therapeutic product candidates to treat
autoimmune and inflammatory diseases and cancer. The company's
mission is to develop a variety of first-in-class and best-in-class
product candidates, customized for optimal safety, efficacy, and
convenience that it believes may offer improved patient
experiences. Trubion's current product candidates are novel single-
chain protein, or SMIP(TM), therapeutics, and are designed using
its custom drug assembly technology. Trubion's product pipeline
includes CD20-directed candidates such as TRU-015 and SBI-087 for
autoimmune and inflammatory diseases, developed under the company's
Wyeth collaboration. Trubion's product pipeline also includes
Trubion's proprietary product candidate, TRU-016, a novel
CD37-targeted therapy for the treatment of B-cell malignancies that
is currently in Phase 1/2 clinical evaluation. In addition to
Trubion's current product candidates, the company is also
developing additional alliance and proprietary product candidates
that build on its product development experience. More information
is available in the investors section of Trubion's website:
investors.trubion.com. Forward-Looking Statements Certain
statements in this release may constitute "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act of 1934 and Section 27A of the Securities Act of 1933.
These statements include, but are not limited to, those related to
the company's future clinical development programs and the timing
thereof, the company's future regulatory filings and the timing and
outcome thereof and the company's expected financial and operating
results. These statements are based on current expectations and
assumptions regarding future events and business performance and
involve certain risks and uncertainties that could cause actual
results to differ materially. These risks include, but are not
limited to, risks associated with the company's Wyeth
collaboration, including Wyeth's control over development
timelines, the risks that the Company is unable to advance its
clinical development programs and regulatory applications and
action at the rate it expects, including the risk that the
Company's Phase 1/2 clinical evaluation of TRU-016 may not be
successful, the risk that the Company does not achieve the
financial and operating results it expects, and such other risks as
identified in the company's quarterly report on Form 10-Q for the
period ended March 31, 2008, and from time to time in other reports
filed by Trubion with the U.S. Securities and Exchange Commission.
These reports are available on the Investors page of the company's
corporate Web site at http://www.trubion.com/. Trubion undertakes
no duty to update any forward-looking statement to conform the
statement to actual results or changes in the company's
expectations. Contact: Jim DeNike Senior Director, Corporate
Communications Trubion Pharmaceuticals Inc. (206) 838-0500 Waggener
Edstrom Healthcare Amy Petty Senior Account Executive (617)
576-5788 TRBN-G DATASOURCE: Trubion Pharmaceuticals Inc. CONTACT:
Jim DeNike, Senior Director, Corporate Communications of Trubion
Pharmaceuticals Inc., +1-206-838-0500, ; or Amy Petty, Senior
Account Executive of Waggener Edstrom Healthcare, +1-617-576-5788,
, for Trubion Pharmaceuticals Inc. Web site:
http://www.trubion.com/
Copyright
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From Jul 2023 to Jul 2024